PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Price & Overview

NASDAQ:PACB • US69404D1081

Current stock price

1.36 USD
+0.03 (+2.26%)
At close:
1.36 USD
0 (0%)
Pre-Market:

The current stock price of PACB is 1.36 USD. Today PACB is up by 2.26%. In the past month the price decreased by -20.47%. In the past year, price increased by 4.62%.

PACB Key Statistics

52-Week Range0.85 - 2.73
Current PACB stock price positioned within its 52-week range.
1-Month Range1.25 - 1.8
Current PACB stock price positioned within its 1-month range.
Market Cap
410.72M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.83
Dividend Yield
N/A

PACB Stock Performance

Today
+2.26%
1 Week
-2.16%
1 Month
-20.47%
3 Months
-26.09%
Longer-term
6 Months +7.09%
1 Year +4.62%
2 Years -63.73%
3 Years -88.26%
5 Years -95.92%
10 Years -84.00%

PACB Stock Chart

PACIFIC BIOSCIENCES OF CALIF / PACB Daily stock chart

PACB Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to PACB. When comparing the yearly performance of all stocks, PACB is a bad performer in the overall market: 77.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PACB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PACB. PACB has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PACB Earnings

On February 12, 2026 PACB reported an EPS of -0.12 and a revenue of 44.65M. The company beat EPS expectations (20.24% surprise) and beat revenue expectations (2.91% surprise).

Next Earnings DateApr 7, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.12
Revenue Reported44.645M
EPS Surprise 20.24%
Revenue Surprise 2.91%

PACB Forecast & Estimates

16 analysts have analysed PACB and the average price target is 2.48 USD. This implies a price increase of 82.14% is expected in the next year compared to the current price of 1.36.

For the next year, analysts expect an EPS growth of 71.86% and a revenue growth 10.42% for PACB


Analysts
Analysts76.25
Price Target2.48 (82.35%)
EPS Next Y71.86%
Revenue Next Year10.42%

PACB Groups

Sector & Classification

PACB Financial Highlights

Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -1.83. The EPS decreased by -11.59% compared to the year before.


Income Statements
Revenue(TTM)160.00M
Net Income(TTM)-546.38M
Industry RankSector Rank
PM (TTM) N/A
ROA -69.68%
ROE -10214.54%
Debt/Equity 120.65
Chartmill High Growth Momentum
EPS Q2Q%75.51%
Sales Q2Q%13.82%
EPS 1Y (TTM)-11.59%
Revenue 1Y (TTM)3.89%

PACB Ownership

Ownership
Inst Owners59.46%
Shares302.00M
Float275.10M
Ins Owners0.75%
Short Float %13.88%
Short Ratio5.14

PACB Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
TMO THERMO FISHER SCIENTIFIC INC18.95174.596B
DHR DANAHER CORP22.54135.34B
BRKRP BRUKER CORP - BRKR 6 3/8 09/01/28122.4740.288B
A AGILENT TECHNOLOGIES INC16.7131.614B
WAT WATERS CORP19.9628.451B
IQV IQVIA HOLDINGS INC12.8727.68B
MTD METTLER-TOLEDO INTERNATIONAL25.5624.37B
ILMN ILLUMINA INC22.818.238B
WST WEST PHARMACEUTICAL SERVICES29.6617.307B
MEDP MEDPACE HOLDINGS INC26.0212.874B
RVTY REVVITY INC15.699.668B
TEM TEMPUS AI INC-CL A N/A9.096B
TECH BIO-TECHNE CORP21.947.636B

About PACB

Company Profile

PACB logo image Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Company Info

IPO: 2010-10-27

PACIFIC BIOSCIENCES OF CALIF

1305 O'brien Drive

Menlo Park CALIFORNIA 94025 US

CEO: Christian O. Henry

Employees: 575

PACB Company Website

PACB Investor Relations

Phone: 16505218000

PACIFIC BIOSCIENCES OF CALIF / PACB FAQ

What does PACIFIC BIOSCIENCES OF CALIF do?

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 485 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.


Can you provide the latest stock price for PACIFIC BIOSCIENCES OF CALIF?

The current stock price of PACB is 1.36 USD. The price increased by 2.26% in the last trading session.


Does PACIFIC BIOSCIENCES OF CALIF pay dividends?

PACB does not pay a dividend.


What is the ChartMill rating of PACIFIC BIOSCIENCES OF CALIF stock?

PACB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists PACB stock?

PACB stock is listed on the Nasdaq exchange.


How is the valuation of PACIFIC BIOSCIENCES OF CALIF (PACB) based on its PE ratio?

PACIFIC BIOSCIENCES OF CALIF (PACB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.83).


What is the employee count for PACB stock?

PACIFIC BIOSCIENCES OF CALIF (PACB) currently has 575 employees.